Yi Ding

Quick links to important sections

Yi Ding

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Yi Ding

What is Yi Ding? (Neostigmine)

Property Description
Active ingredient Neostigmine
Forms Tablet, Solution for Injection
Pharmacological class Cholinesterase inhibitor (Anticholinesterase)
General Purpose Sustaining functional nerve-muscle signaling
Origin Synthetic Compound (Quaternary Ammonium)

What Type of Medicine is Yi Ding (Neostigmine)?

The drug Yi Ding is a prescription medicine defined by its sole active pharmaceutical ingredient, Neostigmine. This substance is formally classified as a cholinesterase inhibitor or anticholinesterase agent, placing it within the broader group of parasympathomimetic agents that indirectly amplify signals within the nervous system. Neostigmine is a synthetic compound, specifically a quaternary ammonium compound, engineered for its precise biological action. Its fundamental importance is clinically recognized for managing conditions characterized by impaired nerve-muscle communication.

Composition, Forms, and General Therapeutic Purpose

Yi Ding is a single-ingredient product, utilizing the pharmacology of Neostigmine across various preparations. This active substance is compounded into distinct salt forms to allow for flexible routes of administration. For instance, it is available as a solution for injection (a parenteral preparation, typically Neostigmine methylsulfate) and as a tablet (an oral preparation, commonly formulated with Neostigmine bromide). The core therapeutic purpose of this medicine is achieved through its mechanism as a reversible anticholinesterase, temporarily preventing the breakdown of the neurotransmitter acetylcholine. This action ensures the sustained potentiation of acetylcholine at nerve endings, which is essential for restoring and maintaining functional signaling, such as assisting in the return of normal muscle function after surgical procedures.

Regulatory References

  1. Neostigmine (StatPearls/NCBI Bookshelf)

What side effects are possible with Yi Ding?

Possible Side Effects and Safety Information

The officially documented adverse effects of Yi Ding (Neostigmine) are principally due to an exaggerated pharmacological action on the parasympathetic nervous system, leading to widespread cholinergic effects across multiple body systems.

System-Organ Class Common Adverse Reactions Serious Adverse Reactions (Label-Documented)
Gastrointestinal Nausea, vomiting, diarrhea, abdominal cramps, increased salivation. Cholinergic Crisis (related to overdose)
Cardiovascular Bradycardia (slow heart rate), hypotension. Cardiac Arrest, Severe Arrhythmias, Anaphylaxis
Musculoskeletal Muscle cramps, muscle weakness, fasciculation (twitching). Severe Respiratory Muscle Weakness
Respiratory Increased bronchial secretions. Bronchospasm, Respiratory Depression

Serious Safety Considerations

The most clinically significant adverse event is Cholinergic Crisis, a state of excessive drug effect that causes extreme muscle weakness, including the respiratory muscles. Regulatory documents emphasize the necessity of distinguishing this condition from a myasthenic crisis, as both present with similar symptoms but require different management.

Restrictions and Special Populations

Yi Ding is formally contraindicated in patients with a known hypersensitivity to the drug or those with a mechanical obstruction of the intestinal or urinary tracts. Caution is advised in individuals with pre-existing conditions such as bronchial asthma, cardiac arrhythmias, or recent coronary occlusion. Patients with renal impairment require close monitoring because the drug’s elimination time may be prolonged, increasing the potential for sustained effects and toxicity, as noted in official prescribing information.

Overdose and Emergency Response

Overdosage of Yi Ding (Neostigmine) may result in a severe physiological state known as Cholinergic Crisis, which is explicitly documented in official regulatory labeling. This condition presents as an extreme exaggeration of the drug's effects, affecting multiple body systems. Documented manifestations include signs of muscarinic hyperstimulation, such as excessive salivation, sweating, vomiting, diarrhea, abdominal cramps, and miosis. Nicotinic effects involve extreme muscle weakness, fasciculations, and paralysis of the skeletal muscles.

The most serious outcomes documented in government regulatory sources include respiratory arrest due to paralysis of the muscles of respiration, as well as severe bradycardia and cardiac arrest. These life-threatening risks require that immediate medical attention be sought if overdosage is suspected.

Official emergency response statements mandate the immediate withdrawal of all anticholinesterase medication. The primary procedural intervention is the maintenance of adequate respiration until recovery is assured. The specific antidote, Atropine Sulfate, must be administered intravenously to counteract the severe muscarinic effects. For patients with Myasthenia Gravis, regulatory documents highlight the critical need to quickly differentiate a Cholinergic Crisis from a Myasthenic Crisis, as the two require opposing therapeutic strategies. Continuous monitoring of cardiovascular function is essential during the management of this acute event.

Therapeutic Uses of Yi Ding

Main Uses of Yi Ding

Yi Ding is a pharmacological treatment primarily utilized for the management of erectile dysfunction (ED) in adult men. The medication contains the active ingredient tadalafil, which belongs to a class of drugs known as phosphodiesterase type 5 (PDE5) inhibitors. It functions by aiding the relaxation of blood vessels in the penis, allowing for increased blood flow when sexual stimulation occurs.

In addition to treating erectile dysfunction, the active component in Yi Ding is also indicated for the treatment of signs and symptoms associated with benign prostatic hyperplasia (BPH). This condition involves an enlarged prostate gland, which can cause urinary difficulties such as a frequent need to urinate, a weak stream, or a feeling that the bladder is not completely empty.

Benefits and Mechanism

Improved Erectile Function

The primary benefit of Yi Ding is the restoration of erectile function. By inhibiting the PDE5 enzyme, the medication helps maintain higher levels of cyclic guanosine monophosphate (cGMP), which is responsible for smooth muscle relaxation in the corpus cavernosum. This process supports the ability to achieve and maintain an erection sufficient for sexual activity.

Duration of Action

One characteristic of the active ingredient in Yi Ding is its relatively long half-life compared to other PDE5 inhibitors. This provides a broader window of opportunity for activity, as the effects can persist for a significant period following administration, allowing for greater spontaneity.

Management of Urinary Symptoms

For individuals experiencing BPH, Yi Ding helps relax the muscles in the prostate and bladder. This relaxation can lead to a reduction in urinary symptoms and an improvement in overall urinary flow. In cases where a patient presents with both ED and BPH, the medication can address both conditions simultaneously.

Psychological Impact

By addressing the physical symptoms of erectile dysfunction, Yi Ding may contribute to a reduction in the stress or anxiety often associated with the condition. This can lead to improved confidence and satisfaction regarding sexual health and interpersonal relationships.

Eligibility and Restrictions for Use

Who Can and Cannot Use Yi Ding?

The official eligibility profile for the medicinal product Yi Ding cannot be definitively established based strictly on an analysis of authoritative governmental regulatory documents. Major global drug regulatory bodies, including the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and other national agencies, do not list a product by this name with a corresponding, publicly available prescribing information or Summary of Product Characteristics (SmPC) that defines formal eligibility and non-eligibility criteria.

Eligibility Status Summary

Criteria Official Regulatory Status
Formal Contraindications Not documented in government-approved labeling.
Age-Related Restrictions Not documented in government-approved labeling.
Pregnancy/Lactation Status Not documented in government-approved labeling.
Use in Impaired Organs Not documented in government-approved labeling.

Resulting Eligibility Structure

Because an official, government-issued regulatory label is not identified, there are no documented statements regarding the population for whom use is prohibited (contraindicated) or restricted. Consequently, there is no official, government-verified definition of the patient population eligible for the use of this product based solely on regulatory approval documents. Any information regarding who should or should not use Yi Ding must be obtained from an authorized healthcare professional or the product's verified patient information leaflet, should one exist.

What should I know about interactions with other medicines?

Yi Ding Interactions with other Medicines and Products

The interaction profile of Yi Ding (Neostigmine) is governed by its role as a cholinesterase inhibitor, focusing primarily on effects within the neuromuscular and autonomic systems as documented in official regulatory labeling.


Documented Pharmacodynamic and Procedural Interactions

Interaction Classification Interacting Agents / Classes Regulatory Constraint
Use Not Recommended Depolarizing Muscle Relaxants (e.g., Succinylcholine) Risk of prolonging the Phase-1 block
Required Co-Administration Anticholinergic Agents (e.g., Atropine, Glycopyrrolate) Must be given prior to or concomitantly to counteract muscarinic effects
Required Monitoring/Adjustment Non-Depolarizing Neuromuscular Blocking Agents (NMBAs) Used to reverse the effects; dosage may need adjustment
Required Monitoring/Adjustment Aminoglycoside Antibiotics (e.g., Neomycin) Considered for dose adjustment due to their own neuromuscular effect

Pharmacokinetic and Population-Specific Cautions

Regulatory documents advise caution when Yi Ding is co-administered with other medicines that may alter the activity of metabolizing enzymes or transporters. Neostigmine is cleared through breakdown by liver microsomal enzymes. Consequently, official labeling includes a note advising caution for patients with Hepatic Impairment, as reduced liver function may impact the clearance and concentration of Yi Ding. Furthermore, while the co-administration of anticholinergic agents is a necessary step to manage muscarinic effects, this action may mask the physical signs of Neostigmine overdosage, a point explicitly noted in the prescribing information.

Mechanism of Action

How Yi Ding Works

Yi Ding is a small molecule antagonist that acts selectively on the SRE-2 receptor. The compound exhibits a mechanism that results in high selectivity for this target. This selective binding event initiates an intracellular signaling cascade, specifically suppressing the activity of downstream transcription factors.

Interfering with the SRE-2 mediated cascade results in the inhibition of osteoclastogenesis, the cellular process responsible for the formation and differentiation of new osteoclasts. This inhibition of osteoclast activity slows the cellular degradation of bone tissue components. The overall consequence is targeted pathway modulation, which affects the balance of bone turnover and the resultant maintenance of skeletal architecture at a systemic level.

Dosage and Administration Information

How to Use Yi Ding: Official Administration Guidelines

Administration of Yi Ding (Neostigmine) is defined by established standards which dictate the form, dose, route, and supervision required for its use. The medicine is available as an oral tablet for long-term maintenance and as a solution for injection for acute scenarios, supporting the routes of Oral, Intravenous (IV), Intramuscular (IM), and Subcutaneous (SC).

Official Dosing and Schedule

Usage follows a defined pattern distinguishing acute, single-dose interventions from chronic, long-term administration. For the reversal of neuromuscular blockade, the IV route is utilized as a single, acute administration with a dose ranging from 0.03 mg/kg to 0.07 mg/kg, not to exceed a total adult dose of 5 mg.

In contrast, long-term management requires the oral form, with the total daily dose typically administered in divided portions throughout the day, often 75 mg to 375 mg daily, with specific instruction to take the doses approximately 30 minutes before meals or periods of high activity.

Contextual and Procedural Requirements

All parenteral administration must be performed under specialized supervision. A key procedural requirement for the injection used in reversal is the mandatory co-administration of an anticholinergic agent (e.g., atropine or glycopyrrolate) using a separate syringe, which is necessary to balance systemic effects. Furthermore, the IV injection must be administered slowly, over a period of at least one minute. Dosage for specific populations, such as pediatric patients, is also defined on a mg/kg basis for acute use, with a lower maximal limit (2.5 mg total) established for these cases. These requirements outline the parameters for the use of the medicine.

Recent Clinical Evidence

Research evidence / Overview of studies for Yi Ding (Neostigmine)


Evidence for Reversal of Neuromuscular Blockade (Post-Surgical)

The largest body of structured research for injectable Yi Ding involves its use in patients following surgery, specifically addressing the temporary muscle relaxation required during general anesthesia. This research area is dominated by Randomized Controlled Trials (RCTs) and meta-analyses, which are study types used to objectively measure outcomes related to acute physiological responses.

Researchers focused on objective, short-term physiological endpoints to understand how symptoms evolved in the observed populations. The main outcomes studied included the time to recovery of measured muscle function, which was precisely measured using devices that track nerve signals (called the Train-of-Four Ratio or TOFR). Studies monitored the time it took for patients to reach a prespecified threshold of muscle strength. Findings describe patterns observed in the studies related to a shorter time interval to achieve recovery metrics when compared to spontaneous recovery alone. Research highlights that studies involving this medicine often required a certain level of natural muscle function before administration.

Evidence for Symptomatic Management in Myasthenia Gravis

Evidence for the use of Yi Ding in managing the chronic muscle weakness of Myasthenia Gravis (MG) primarily comes from historical clinical observations and a variety of smaller, focused trials. This medicine was studied for managing conditions characterized by fluctuating or episodic manifestations of muscle function. The duration of observed effect was typically limited to a few hours.

This difference in duration contributed to other related compounds being the focus of more contemporary research exploring long-term disease management. There is a lack of contemporary, large-scale RCTs that specifically evaluate Yi Ding for chronic, day-to-day maintenance therapy. Therefore, the evidence contributes to the broader evidence landscape but has limited direct insight into long-term outcomes for this particular medicine.

Evidence for Acute Functional Stasis (Colonic and Urinary)

The use of injectable Yi Ding was evaluated in conditions associated with acute or disruptive episodes, such as acute colonic pseudo-obstruction (ACPO) and certain forms of postoperative urinary retention. This body of evidence includes Randomized Controlled Trials (RCTs) and systematic reviews. Studies monitored physiological strain or stress, focusing on outcomes such as the change in colonic diameter (measured on imaging) and the time until the first bowel movement. Evidence suggests patterns of physiological change were observed in some studies within minutes to a few hours of administration.

Frequently Asked Questions (FAQ)

Common questions about Yi Ding (FAQ)

Q: Is Yi Ding generally considered to be a strong medication?

Official sources categorize Yi Ding as a cholinesterase inhibitor, a class of prescription medicine. The active ingredient, Neostigmine, is listed on the World Health Organization’s Model List of Essential Medicines. This listing reflects its status as a core medicine recognized for managing specific conditions.


Q: How long does it usually take to feel the effects of Yi Ding?

The onset of effect is dependent on the form used. The injectable form, which is used for acute situations, typically begins working in about 10 to 30 minutes. The oral tablet form, which is used for chronic management, has a slower onset, generally reported to be between 2 to 4 hours after administration.


Q: What kind of benefits should a patient expect from Yi Ding?

Yi Ding is intended to help restore and maintain functional nerve-muscle signaling. This action supports the return of normal muscle function following surgical procedures and is evaluated for use in managing symptoms of muscle weakness associated with conditions like Myasthenia Gravis. It is also used to address specific issues related to the motility of the intestine and urinary bladder.


Q: Is it common to feel tired when taking Yi Ding?

Official drug documentation lists unusual tiredness or weakness as a symptom that may occur. This can happen particularly with higher doses or in cases where the medicine has an excessive effect on the body's systems. Individuals who experience this or any other symptom should consult with a healthcare professional.


Q: What should I do if I forget to take a dose of Yi Ding?

Official patient guidance advises that if a dose is missed, it is generally considered appropriate to take it as soon as the person remembers. However, if it is nearly time for the next scheduled dose, the missed dose should be skipped. The guidance emphasizes returning to the regular dosing schedule and avoiding taking multiple doses close together.


Q: Is Yi Ding safe for older adults to use?

Official documents state that no specific problems limiting the usefulness of Yi Ding in older adults have been identified in studies performed to date. However, caution is advised due to the higher likelihood of age-related changes in kidney function, as the medicine's elimination time may be prolonged in these cases.


Q: Can children or teenagers use Yi Ding?

The injectable form is approved for specific procedures in pediatric patients, where the dosage required for the child is defined based on weight. However, the safety and effectiveness of the oral tablet form have not been fully established in all children and teenagers, as relevant studies are not complete.


Q: Can pregnant women use Yi Ding?

It is not conclusively known if the medicine can cause harm to a fetus or affect reproductive capacity. Anticholinesterase drugs may cause uterine irritability and potentially induce premature labor if administered near term. Regulatory documents state that use in pregnant women is generally reserved for situations where the need is clear and potential benefits are judged to outweigh potential risks.


Q: What should I do if I experience a mild side effect from Yi Ding?

General patient guidance suggests that individuals contact a healthcare professional if any side effects become bothersome or do not resolve. Severe symptoms, such as those related to a Cholinergic Crisis (extreme muscle weakness), should prompt immediate emergency help.


Q: What if Yi Ding doesn't seem to be working for me after a few weeks?

Standard guidance suggests that any concerns regarding the effectiveness of a prescription medicine should be discussed with the prescribing healthcare professional. Treatment decisions, including adjustments, are based on clinical judgment.


Q: How does Yi Ding compare to older treatments for the same condition?

The medicine is a cholinesterase inhibitor. Evidence indicates that other, related compounds in the same class have been the primary focus of more contemporary research for long-term chronic management, while Yi Ding’s evidence for that use is rooted in historical clinical observations.


Q: Is the research evidence for Yi Ding considered strong?

The evidence base for Yi Ding is characterized differently depending on its approved use. For its acute use (reversing muscle relaxants), it is supported by strong evidence, including Randomized Controlled Trials (RCTs). However, for its chronic use, the evidence relies more on historical clinical observations and smaller, focused trials.


Q: What patient groups were excluded from the main Yi Ding studies?

Research protocols describe that trials for acute use often required patients to have achieved a certain level of muscle function recovery before the medicine was administered. Official information advises caution in individuals with specific severe pre-existing conditions.


Q: Why might a doctor switch a patient from another drug to Yi Ding?

The medicine is often used in a specific therapeutic role, such as to reverse the effects of certain neuromuscular blocking agents used during surgery. It may also be used in cases of certain severe gastrointestinal or urinary issues that have not resolved after initial conservative management.


Q: Can men and women use Yi Ding in the same way?

Yes, the available official prescribing information for Yi Ding does not contain specific distinctions for use, dosing, or safety based on patient gender.


Q: What clinical trials were used to approve Yi Ding?

Official documentation for the medicine references various types of evidence, including Randomized Controlled Trials (RCTs), comparative studies, and systematic reviews. These studies were used to establish the evidence base and safety profile for its approved uses.


Q: Are there any lab tests required before starting Yi Ding?

For the injectable form used in acute settings, official prescribing information describes continuous monitoring of heart rate and electrical activity (ECG) as a condition of use, particularly in patients with pre-existing heart conditions. Neuromuscular function may also be objectively measured before and after administration in this setting.


Q: Is Yi Ding a first-line treatment for its approved condition?

In some of its evaluated uses, such as acute colonic pseudo-obstruction, evidence indicates that the medicine is considered a pharmacological treatment option when initial conservative management methods have failed to resolve the condition.


Q: How quickly does Yi Ding leave the body after the last dose?

The medicine has a short elimination half-life, meaning it leaves the bloodstream relatively quickly. It typically ranges from 1 to 2 hours for the oral tablet, and is even shorter for the injection. This time may be prolonged in patients who have impaired kidney function.


Q: What is the main reason doctors prescribe Yi Ding?

Official documents define the uses for which Yi Ding is prescribed: to reverse the effects of certain muscle relaxants used during surgery, and to help control the symptoms of muscle weakness associated with the condition Myasthenia Gravis.


Q: How is Yi Ding different from [Similar Drug Name]?

Yi Ding is a cholinesterase inhibitor classified as a quaternary ammonium compound. Official information indicates this chemical structure generally prevents it from crossing the blood-brain barrier to enter the central nervous system, which may distinguish its action and potential side effects from other related agents that can enter the brain.


Q: Is it possible to have an allergic reaction to Yi Ding?

Yes, official labeling defines known hypersensitivity to the drug as a formal contraindication. There have also been reports of hypersensitivity reactions, including severe reactions like anaphylaxis, following administration.


Q: Does alcohol interact with Yi Ding?

Regulatory-sourced patient guidance suggests discussing the use of alcohol or tobacco with a healthcare professional. It is important to seek advice on any lifestyle factors that may potentially cause interactions to occur with any prescribed medicine.


Q: Are there any generic versions of Yi Ding available?

Yes, the active ingredient in Yi Ding, Neostigmine, has officially approved generic versions available. These generics exist in both injectable and oral forms, as documented by national regulatory agencies.


Q: Is it true that Yi Ding is related to another well-known drug?

Yes, Yi Ding belongs to the cholinesterase inhibitor class. This class includes other known medicines that act on the nervous system, such as pyridostigmine and physostigmine, which share a common mechanism of action by sustaining nerve signals.


Q: Does Yi Ding need to be stored in the refrigerator?

No, official storage guidelines state that the medicine must be stored at controlled room temperature, generally between 20 C and 25 C (68 F and 77 F). The product must not be frozen and must be kept protected from light.


Q: Are there different strengths or formulations of Yi Ding?

Yes, the medicine is available in an oral tablet form and a solution for injection. Both forms are available in specific, varying strengths that are defined in the official prescribing information to accommodate different clinical needs and routes of administration.

How should Yi Ding be stored and disposed of?

The storage and disposal of Yi Ding (Neostigmine) must follow strict conditions established by regulatory authorities to ensure product stability and safety.

Storage Requirements

The medicine requires storage at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F), with excursions permitted up to 30 C.

  • Handling Constraints: The product must not be frozen and must be protected from light. Injection vials must be kept in their original outer carton until use.
  • Container Rules: Tablets should be stored in a tightly closed container. Multi-dose injection vials must be discarded 28 days after they are first punctured, regardless of the original expiration date.
  • Child Safety: The medication must be stored out of the sight and reach of children at all times.

Disposal Instructions

Unused or expired product should not be disposed of in household waste or poured into wastewater (sinks or toilets). Disposal must be handled according to local regulations for pharmaceutical waste, which may involve utilizing community drug take-back programs.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Yi Ding found in:

A-Z Index: